Global HIV Drugs Market is valued at approximately USD 34.28 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.5% over the forecast period 2024-2032. Human immunodeficiency virus (HIV) is a chronic and life-threatening disease, which can be transferred from one person to another through blood-to-blood and sexual contact. It attacks immune cells known as CD-4 cells, making the body susceptible to infections and other diseases. Over the years, the rise in prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs, which help to prevent the multiplication of the HIV virus, thereby reducing the risk of its transmission. The growth of the HIV drugs market is driven by the rising demand for HIV medications, increased initiatives by various government associations to raise awareness about the diagnosis and management of HIV, and a rise in cases of HIV. For instance, according to the Joint United Nations Program on HIV and AIDS (UNAIDS), 39 million people globally were living with HIV in 2022. Additionally, 1.3 million people became newly infected with HIV, and 630,000 people died from AIDS-related illnesses in the same year.
However, lack high cost of HIV treatment, along with the social stigma and discrimination are the key factors that are substantially halting the growth of the market globally. The pharmaceutical industry continues to invest in research and development efforts to better understand the underlying mechanisms of HIV and develop innovative therapies. This includes exploring new drug targets, conducting clinical trials, and investigating combination therapies. Therefore, the rise in R&D in drug discovery drives the growth of the HIV drugs market size during the forecast period. For instance, in February 2023, Merck & Co., Inc. announced the opening of enrollment in its new Phase 3 clinical program with investigational once-daily islatravir 0.25 mg in combination with doravirine 100 mg (DOR/ISL) for the treatment of HIV-1 infection.
Furthermore, the rise in awareness about HIV leads to more individuals seeking testing and diagnosis. This results in the identification of previously undiagnosed cases, subsequently increasing the demand for HIV drugs to initiate treatment. For instance, the U.S. Agency for International Development and various associations globally have introduced many initiatives and education campaigns for community awareness to address HIV prevention, treatment, and care.
The key regions considered for the global HIV drugs Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America accounted for a major HIV drugs market share in 2023 and is expected to maintain its dominance during the forecast period. The presence of several major players, rise in the number of clinical trials of HIV drugs, availability of advanced healthcare facilities, and high healthcare expenditure from government organizations in the region drive market growth. Whereas, Asia-Pacific is expected to grow at the highest rate during the forecast period. This is attributable to a rise in cases of HIV, as well as an increase in the purchasing power of populated countries such as China and India. The region possesses a huge population base, with China and India being the first and second most populated countries, respectively. A rise in population along with longer life expectancy is expected to drive market growth in Asia-Pacific during the forecast period.
Major market players included in this report are:
GlaxoSmithKline plc
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Cipla Ltd.
Merck & Co., Inc.
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
AbbVie Inc.
Boehringer Ingelheim International GmbH
Teva Pharmaceutical Industries Ltd.
The detailed segments and sub-segment of the market are explained below:
By Medication Class:
Multi-Class Combination Drugs
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Protease Inhibitors (PIs)
Entry Inhibitors
HIV Integrase Strand Transfer Inhibitors
Others
By Distribution Channel:
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.
